GE and Glaxo ally to develop molecular medicine

Article

GE Medical Systems has signed a broad collaborative research agreement with GlaxoSmithKline to bring clinical molecular imaging technologies into the pharmaceutical development process. Their first project will be to advance the diagnosis and treatment

GE Medical Systems has signed a broad collaborative research agreement with GlaxoSmithKline to bring clinical molecular imaging technologies into the pharmaceutical development process. Their first project will be to advance the diagnosis and treatment of chronic obstructive pulmonary disease (COPD). GE is aggressively pursuing noninvasive molecular imaging to detect and monitor disease with specific molecular markers. GlaxoSmithKline has expertise in respiratory science, molecular medicine, and drug development for diseases including COPD. Early research will be done at GE’s Corporate Research and Development site in Schenectady, NY, in collaboration with GlaxoSmithKline’s COPD Clinical Network. Together, the companies hope to develop new medicines and better means for diagnosing and treating COPD.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.